SCHEMBL5661069

SCHEMBL5661069

Cc1cc(C2(c3cc(C)c(O)c(C)c3)C(=O)N(CC#N)c3ccccc32)cc(C)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.50
GPR55 Q9Y2T6 2/20 0.50
LMNA P02545 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 8/20 0.38
USP2 O75604 3/20 0.38
MAPT P10636 4/20 0.36
XBP1 P17861 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659465 0.82 CNR1 (0.55) CNR1GPR55MEN1KMT2AKDM4E
SCHEMBL5659203 0.80 CNR1 (0.52) CNR1GPR55ALDH1A1USP2MAPT
SCHEMBL5661475 0.80 CNR1 (0.38) CNR1GPR55LMNAMEN1KMT2A
SCHEMBL5658731 0.79 CNR1 (0.52) CNR1GPR55LMNAMEN1KMT2A
SCHEMBL14457619 0.78 CNR1 (0.47) CNR1GPR55MEN1KMT2AALDH1A1
SCHEMBL5659726 0.78 TP53 (0.52) CNR1GPR55LMNAMEN1KMT2A
SCHEMBL5658420 0.78 MAPT (0.49) CNR1GPR55MEN1KMT2ACYP2C9
SCHEMBL14457581 0.78 SCN9A (0.51) CNR1GPR55LMNAALDH1A1MAPT
SCHEMBL5660243 0.77 SCN9A (0.53) CNR1GPR55
SCHEMBL5660616 0.77 CNR1 (0.61) CNR1GPR55ALDH1A1USP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 CNR1 362/4885GPR55 77/4885LMNA 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.